-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since 2022, listed pharmaceutical companies have successively released their 2021 performance forecasts.
Overall, the majority of pharmaceutical companies with pre-increased performance
.
On January 20, another 4 pharmaceutical companies announced the pre-growth of their performance, namely Jiu'an Medical, Yirui Bio, Aoxiang Pharmaceutical, and Sanyou Medical.
Among them, Yirui Bio and Jiu'an Medical are expected to increase their net profit by more than 200%.
%
.
Jiu'an Medical: Net profit increased by 271.
40% to 395.
19% Jiu'an Medical released the 2021 annual report performance forecast today, and it is expected to achieve a net profit of 900 million to 1.
2 billion yuan in 2021, an increase of 271.
40% to 395.
19%, basic earnings per share 1.
9799 yuan to 2.
6399 yuan
.
The net profit in the same period last year was 242 million yuan, and the basic earnings per share was 0.
56 yuan
.
Regarding the reasons for the growth in performance, the company stated that the main reason is that the sales performance of the company's antigen home self-test OTC kit products in the U.
S.
market has increased significantly, which will lead to a substantial increase in operating performance in 2021
.
It is worth mentioning that, affected by the pre-increase in performance, today Jiu'an Medical once again rose to the daily limit, at 77.
66 yuan per share
.
At present, the company's total market value is 37.
17 billion yuan, corresponding to a price-earnings ratio of about 40 times in 2021
.
According to Wind data, the number of shareholders of Jiu'an Medical in the fourth quarter of 2021 has increased by more than 40,000 compared with the previous quarter, and some shareholders may have harvested more than 600 million yuan
.
Yirui Bio: Net profit increased by 236.
16% to 297.
28% Yirui Bio expects to achieve a net profit of 220 million yuan to 260 million yuan from January 1, 2021 to December 31, 2021, an increase of 236.
16% to 297.
28% , and obtained a net profit of 65.
4451 million yuan in the same period last year
.
For the change in performance, the company attributed to two aspects, one of which is the surge in demand for antigen self-testing agents in overseas markets
.
Relying on the advantages of technology and quality control, the company's orders and revenue for semi-finished products of antigen detection reagents and supporting solutions have increased accordingly, which will promote the substantial growth of performance in 2021
.
In addition, during the reporting period, it is estimated that the impact of non-recurring gains and losses on the company's net profit is about 22 million yuan, mainly from government subsidies and wealth management income
.
Aoxiang Pharmaceutical: Net profit increased by 50.
86% to 70.
44% Aoxiang Pharmaceutical released an announcement on the pre-increase in performance, and it is expected that the net profit for 2021 will be 131 million to 148 million yuan, an increase of 50.
86% to 70.
44%, compared with the same period last year The net profit was 86.
836 million yuan, and the basic earnings per share was 0.
39 yuan
.
According to the data, Aoxiang Pharmaceutical is mainly engaged in the research and development, production and sales of characteristic APIs and pharmaceutical intermediates, as well as providing customized production and research and development services for customers
.
The main products of the API and pharmaceutical intermediates business include entecavir, bicyclol, sitafloxacin,
etc.
At the opening of the market today, Aoxiang Pharmaceutical will soon have a daily limit.
This is also the third daily limit that Aoxiang Pharmaceutical has harvested since January 12 and January 19 this year
.
According to statistics, from January 12 to today's midday trading, Aoxiang Pharmaceutical's stock price has risen by 41.
33%
.
Sanyou Medical: Net profit increased by 48.
45% to 60.
26%.
The 2021 annual report performance forecast released by Sanyou Medical shows that the expected performance for 2021 is as follows: net profit of 176 million to 190 million yuan, an increase of 48.
45% to 60.
26%.
Net profit of 118 million yuan was achieved in the same period
.
It is reported that the main business of Sanyou Medical is the research and development, production and sales of medical orthopedic implants.
The main products are spinal implants and trauma implants
.
Regarding the reasons for the growth in performance, the company stated that the epidemic situation in most regions in 2021 has been effectively controlled, and orthopaedic surgery in hospitals will be carried out in an orderly manner.
At the same time, the company will continue to strengthen market development and channel construction, and the company's product sales will grow steadily
.
Overall, the majority of pharmaceutical companies with pre-increased performance
.
On January 20, another 4 pharmaceutical companies announced the pre-growth of their performance, namely Jiu'an Medical, Yirui Bio, Aoxiang Pharmaceutical, and Sanyou Medical.
Among them, Yirui Bio and Jiu'an Medical are expected to increase their net profit by more than 200%.
%
.
Jiu'an Medical: Net profit increased by 271.
40% to 395.
19% Jiu'an Medical released the 2021 annual report performance forecast today, and it is expected to achieve a net profit of 900 million to 1.
2 billion yuan in 2021, an increase of 271.
40% to 395.
19%, basic earnings per share 1.
9799 yuan to 2.
6399 yuan
.
The net profit in the same period last year was 242 million yuan, and the basic earnings per share was 0.
56 yuan
.
Regarding the reasons for the growth in performance, the company stated that the main reason is that the sales performance of the company's antigen home self-test OTC kit products in the U.
S.
market has increased significantly, which will lead to a substantial increase in operating performance in 2021
.
It is worth mentioning that, affected by the pre-increase in performance, today Jiu'an Medical once again rose to the daily limit, at 77.
66 yuan per share
.
At present, the company's total market value is 37.
17 billion yuan, corresponding to a price-earnings ratio of about 40 times in 2021
.
According to Wind data, the number of shareholders of Jiu'an Medical in the fourth quarter of 2021 has increased by more than 40,000 compared with the previous quarter, and some shareholders may have harvested more than 600 million yuan
.
Yirui Bio: Net profit increased by 236.
16% to 297.
28% Yirui Bio expects to achieve a net profit of 220 million yuan to 260 million yuan from January 1, 2021 to December 31, 2021, an increase of 236.
16% to 297.
28% , and obtained a net profit of 65.
4451 million yuan in the same period last year
.
For the change in performance, the company attributed to two aspects, one of which is the surge in demand for antigen self-testing agents in overseas markets
.
Relying on the advantages of technology and quality control, the company's orders and revenue for semi-finished products of antigen detection reagents and supporting solutions have increased accordingly, which will promote the substantial growth of performance in 2021
.
In addition, during the reporting period, it is estimated that the impact of non-recurring gains and losses on the company's net profit is about 22 million yuan, mainly from government subsidies and wealth management income
.
Aoxiang Pharmaceutical: Net profit increased by 50.
86% to 70.
44% Aoxiang Pharmaceutical released an announcement on the pre-increase in performance, and it is expected that the net profit for 2021 will be 131 million to 148 million yuan, an increase of 50.
86% to 70.
44%, compared with the same period last year The net profit was 86.
836 million yuan, and the basic earnings per share was 0.
39 yuan
.
According to the data, Aoxiang Pharmaceutical is mainly engaged in the research and development, production and sales of characteristic APIs and pharmaceutical intermediates, as well as providing customized production and research and development services for customers
.
The main products of the API and pharmaceutical intermediates business include entecavir, bicyclol, sitafloxacin,
etc.
At the opening of the market today, Aoxiang Pharmaceutical will soon have a daily limit.
This is also the third daily limit that Aoxiang Pharmaceutical has harvested since January 12 and January 19 this year
.
According to statistics, from January 12 to today's midday trading, Aoxiang Pharmaceutical's stock price has risen by 41.
33%
.
Sanyou Medical: Net profit increased by 48.
45% to 60.
26%.
The 2021 annual report performance forecast released by Sanyou Medical shows that the expected performance for 2021 is as follows: net profit of 176 million to 190 million yuan, an increase of 48.
45% to 60.
26%.
Net profit of 118 million yuan was achieved in the same period
.
It is reported that the main business of Sanyou Medical is the research and development, production and sales of medical orthopedic implants.
The main products are spinal implants and trauma implants
.
Regarding the reasons for the growth in performance, the company stated that the epidemic situation in most regions in 2021 has been effectively controlled, and orthopaedic surgery in hospitals will be carried out in an orderly manner.
At the same time, the company will continue to strengthen market development and channel construction, and the company's product sales will grow steadily
.
